JXL069

JXL069
Identifiers
	IUPAC name 3-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridin-3-yl]-2-cyanoprop-2-enoic acid;
CAS Number	2260696-63-5;
PubChem CID	175007307;
ChemSpider	123961728;
Chemical and physical data
Formula	C20H11F6N3O2
Molar mass	439.317 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC2=C(N=C1)N(C=C2C=C(C#N)C(=O)O)CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F;
	InChI InChI=1S/C20H11F6N3O2/c21-19(22,23)14-4-11(5-15(7-14)20(24,25)26)9-29-10-13(6-12(8-27)18(30)31)16-2-1-3-28-17(16)29/h1-7,10H,9H2,(H,30,31); Key:IGVIZFSCSSEYDA-UHFFFAOYSA-N;

JXL069 is an experimental drug originally developed at the University of California and licensed for development to Pelage Pharmaceuticals, which acts as a potent and selective mitochondrial pyruvate carrier (MPC) inhibitor that disrupts pyruvate import into mitochondria. It has been researched as a potential treatment for androgenetic alopecia and shows positive results in animal studies. Pelage Pharmaceuticals currently has a candidate molecule PP405 in Phase II human clinical trials for hair loss formulated as a topical cream for the scalp,^[1]^[2] though it is unclear if this is JXL069 or a related molecule. Mitochondrial pyruvate carrier inhibitors also have potential for the treatment of cancer, so a large number of related molecules have also been developed, of which JXL069 was among the most effective tested so far for treatment of hair loss.^[3]^[4]^[5]^[6]^[7]^[8]

Quick facts Identifiers, CAS Number ...

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

JXL069

See also

References

Wikiwand - on